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LNCaP
DU145
PC3Many cancer cells have an unusual ability to grow in hypoxia, but the origins of this metabolic phenotype
remain unclear. We compared the metabolic phenotypes of three common prostate cancer cell models (LNCaP,
DU145, PC3), assessing energy metabolism, metabolic gene expression, and the response to various culture
contexts (in vitro and xenografts). LNCaP cells had a more oxidative phenotype than PC3 and DU145 cells based
upon respiration, lactate production, [ATP], metabolic gene expression, and sensitivity of these parameters to
hypoxia. PC3 and DU145 cells possessed similar Complex II and mtDNA levels, but lower Complex III and IV
activities, and were unresponsive to dinitrophenol or dichloroacetate, suggesting that their glycolytic phenotype
is due to mitochondrial dysfunction rather than regulation. High passage under normoxia converted LNCaP from
oxidative to glycolytic cells (based on respiration and lactate production), and altered metabolic gene
expression. Though LNCaP-derived cells differed from the parental line in mitochondrial enzyme activities, none
differed in mitochondrial content (assessed as cardiolipin levels). When LNCaP-derived cells were grown as
xenografts in immunodeﬁcient mice, there were elements of a hypoxic response (e.g., elevated VEGFmRNA) but
line-speciﬁc changes in expression of select glycolytic, mitochondrial and fatty acid metabolic genes. Low
oxygen in vitro did not inﬂuence the mRNA levels of SREBP axis, nor did it signiﬁcantly alter triglyceride
production in any of the cell lines suggesting that the pathway of de novo fatty acid synthesis is not directly
upregulated by hypoxic conditions. Collectively, these studies demonstrate important differences in the
metabolism of these prostate cancer models. Suchmetabolic differences would have important ramiﬁcations for
therapeutic strategies involving metabolic targets.© 2009 Elsevier B.V. All rights reserved.1. Introduction
Otto Warburg was the ﬁrst to note that solid tumors showed
accelerated glycolysis (glucose→2 lactate) and reduced oxygen
consumption, prompting him to suggest that respiration in cancer
cells was impaired in some manner [1]. Once mitochondria were
identiﬁed as the source of cellular respiration, Warburg's subsequent
studies on isolated mouse ascites cells [2] convinced him that cancer
cells possessed defective mitochondria and that the accelerated rate of
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hate dehydrogenase; G6PDH,
HIF, hypoxia-inducible factor;
y factor 2; OXPHOS, oxidative
pyruvate dehydrogenase; PDK,
ivator 1; PGI, phosphoglucoi-
muscle isoform; SCAP, SREBP
nodeﬁciency; SCO2, synthesis
lement binding protein; TBP,
h factor
1 613 533 6617.
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ll rights reserved.(the Warburg effect). Just as this theory possessed its detractors in
Warburg's era [3], there continues to be vigorous debate about the
origins of this aerobic glycolytic phenotype in cancer cells. In fact,
some cancer cells grown under normoxic conditions show no
evidence of a Warburg effect, with an energy metabolism dominated
by oxidative phosphorylation [4–6]. Such cancer cells may demon-
strate elevated glycolytic rates but only in response to hypoxia in the
microenvironment (i.e., a Pasteur effect) [4]. Nonetheless, many
cancers show a high glycolytic rate/lowmitochondria rate even under
normoxia [4], and it remains unclear whether these differences in
metabolic poise (glycolytic versus oxidative) are speciﬁc to a cancer
type, speciﬁc cell lines, or growth context.
In those cancers with a predisposition toward aerobic glycolysis,
the emergence of the metabolic phenotype appears to be linked to
hypoxic selection. Hypoxia arises within the tumor as growth
outpaces vascularization and selection under hypoxia leads to a
more aggressive, less responsive cancer [7–9]. The aerobic glycolytic
phenotype has been shown to persist upon neovascularization,
suggesting that the phenotype arises from genetic or epigenetic
changes [10]. Many studies have identiﬁed speciﬁc defects in
metabolic enzymes in cancer cells [5] but the origins of the defect
remain unclear in all but a few cancers. It is not clear whether the
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with (i) superior glycolytic potential or (ii) an inferior mitochondrial
function. In tumors or established lines, the metabolic phenotype is a
culmination of the primary genetic/epigenetic lesion (mitochondrial
or glycolytic), secondary genetic/epigenetic changes, and compensa-
tory regulatory responses in gene expression and/or metabolic
control. For example, Matoba et al. [11] recently showed in some
cancers that the loss of the tumor suppressor p53 depresses the
expression of Sco2, a metal chaperone important in cytochrome
oxidase biosynthesis, and the impairment of mitochondrial oxidative
phosphorylation (OXPHOS) leads to a compensatory increase in
glycolytic ﬂux.
Though it is difﬁcult to explore the emergence of cancer
metabolism in real time, some studies have explored the changes in
the energetic phenotype using experimental evolution. Selection of
cells under hypoxia reduced the rate of oxygen consumption and
increased the levels of HIF-1α [12], the transcription factor of an
oxygen-sensitive pathway that regulates genes involved in anaerobic
metabolism, angiogenesis, growth factor signaling and metastasis
[13,14]. In most cases, characterization of changes in aerobic and
anaerobic metabolic pathways in a cancer would not in itself identify
the primary lesion, though they may clarify the regulatory basis of the
existing phenotype of the cancer and point to therapeutic avenues [6].
The loss of mitochondrial function may enable cancer cells to escape
cell death by precluding mitochondrial-induced apoptosis, thus anti-
cancer therapies that improve mitochondrial efﬁcacy may promote
cell death in tumors [15].
In the present study, we take a comprehensive approach to
characterize the metabolic phenotype of three of the most common
prostate cancer cell lines (LNCaP, DU145, and PC3) in an effort to
disentangle the determinants of the oxidative and glycolytic meta-
bolic phenotype in these important models of prostate cancer. Our
ﬁrst goal was to compare the metabolic proﬁle of these lines when
grown under identical conditions in vitro to see if these lines have
fundamental differences in their metabolic properties. To this end, we
assessed the rates of glycolysis and oxidative phosphorylation,
catalytic activities of enzymes of intermediary metabolism (mito-
chondrial, glycolytic, and lipogenic), the expression of genes encoding
critical enzymes and the genetic regulators of their expression. Given
the marked differences in metabolic poise we discovered, we tested
the hypothesis that these lines would differ in their metabolic and
genetic responses to hypoxia. In most cell culture models, there is a
potential for in vitro evolution of the genotype through genetic drift
during passage. Focusing on LNCaP and derived lines, we assessed
how passage/clonal selection affect the metabolic phenotype both in
vitro (in culture) and in vivo (in xenografts). Collectively, these studies
on the relationship between oxidative phosphorylation, aerobic
glycolysis, lipid metabolism and hypoxia in prostate cancer cells
contribute to our understanding of the origins of the aerobic glycolytic
phenotype of prostate and other cancer cells, with important
ramiﬁcations for metabolism-based therapeutic approaches.
2. Materials and methods
2.1. Cell culture and treatments
LNCaP, PC3, and DU145 prostate cancer cell lines were obtained
from the American Type Culture Collection (ATCC, Manassas, VA).
LNCaP was derived in 1977 from a needle aspirate biopsy of a
supraclavicular lymph node from a 50-year-old white male with stage
D prostatic cancer [16]. LNCaP cells express a mutated form of the
androgen receptor, which leads to some alterations in androgenic
responses [17]. However, these cells produce the human prostatic
secretory markers prostate speciﬁc antigen (PSA) and prostatic acid
phosphatase (PAP) both in vitro andwhen xenografted into nudemice
[18]. LNCaP cells are responsive to androgens in terms of growthhowever they exhibit aberrant responses to antiandrogens [19]. The
PC3 line was isolated from a bone metastasis of a 62-year-old
Caucasian diagnosed as having undifferentiated grade IV adenocarci-
noma of the prostate. PC3 can grow in soft agar, in suspension culture
and will form tumors in nude mice. It does not respond to androgens
or various growth factors [20,21]. DU145 cells were derived in 1975
from a brain metastasis of prostatic cancer in a 69-year-old white
male. The original metastasis was identiﬁed as moderately differ-
entiated with foci of poorly differentiated cells. DU145 cells grow very
rapidly from low densities. They are neither hormone dependant nor
hormone sensitive in terms of growth [20,22].
LNCaP-luc cells were a gift from Dr. Mark Day (University of
Michigan). They were derived from LNCaP cells that had been
transfected with luciferase constructs and clonally selected. High
passage LNCaP cells (HP-LNCaP) were derived by continuous in vitro
culture of LNCaP cells through approximately 50 passages. To mitigate
potential effects of differences in culture media, we grew all cells in
Dulbecco's Modiﬁed Eagle Medium (DMEM: high glucose with
glutamine, Gibco, Burlington, ON) supplementedwith 10% fetal bovine
serum (FBS, Gibco, Burlington, ON) and 1% penicillin–streptomycin
(Gibco, Burlington, ON), with 5% CO2 and 95% humidity at 37 °C. Acidic
medium was obtained using the standard DMEM mixture replacing
24 mM NaHCO3 with a mixture of 0.94 mM NaHCO3 and 22 mM NaCl.
Hypoxia treatments (2% O2) were performed either in a modular
incubator chamber (Billups-Rothenberg Inc., San Diego, CA) ﬂushed
with 2% O2, 5% CO2 and balance nitrogen, or in an incubator with 5%
CO2 and 2% O2 at 37 °C. Anoxia treatments (0% O2) were performed in
a chamber ﬂushed with 5% CO2 and balance nitrogen. For treatments
with azide, a chemical anoxia mimetic, a ﬁnal concentration of 5 mM
was added to the plates. For sodium dichloroacetate (DCA) studies,
cells were treated with 0.5 mM of the drug for 48. For 2,4-
dinitrophenol (DNP) studies, cells were exposed to a ﬁnal concentra-
tion of 0.1 μM of DNP prior to measurements. This concentration was
established using titrations to achieve the lowest dose capable of
maximally stimulating respiration.
2.2. Oxygen consumption
Respiration was measured in cell suspensions using Clarke-type
electrodes ﬁtted into water-jacketed vessels (Gilson, Middleton, WI).
Cells were trypsinized, centrifuged (3 min at 200 g) and resuspended
in media that was air-saturated at 37 °C. For DCA experiments, cells
grown in the presence of DCA were also assayed for respiration in the
same concentration of DCA.
2.3. Lactate production
To assess the impact of oxygen concentration on lactate produc-
tion, cells were exposed to control (21% O2, 5% CO2, balance N2),
hypoxia (2% O2, 5% CO2, balance N2), or anoxia (5% CO2, balance N2) for
12 h. Cells were collected from the supernatant (via centrifugation)
and the plate (via trypsinization then centrifugation), and aliquots
were centrifuged (1 min at 12,000 g). The supernatant was analyzed
for lactate concentration using the hydrazine-sink method (see ref.
[23]). In brief, media and lactate standards were incubated in 96-well
plates in the presence of NAD+ (2mM), lactate dehydrogenase (1U/ml)
and a glycine-hydrazine buffer (pH 9.2). Lactate production rates were
expressed relative to the cellular protein.
2.4. Enzyme assays
Cells were trypsinized and then centrifuged (3 min at 200 g).
Pellets were washed with phosphate-buffered saline (PBS, 73.1 mM
NaCl, 3.7 mM KCl, 2.2 mM Na2HPO4·7H2O, 8.7 mM K2HPO4, pH 7.4),
ﬂash frozen in liquid nitrogen and stored at −80 °C prior to enzyme
analyses. The cell pellets were resuspended in enzyme extraction
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spectrophotometric assays. The activities of mitochondrial cytochrome
oxidase (COX) and citrate synthase (CS) were determined as previously
described [23]. For lactate dehydrogenase (LDH), pyruvate kinase (PK),
and glyceraldehyde 3-phosphate dehydrogenase (G3PDH) activity, the
absorbance of NADH (340 nm) was measured over 3 min. The assay
buffers were as follows: LDH (50mMHEPES pH 7.4, 0.2 mMNADH, and
2 mM pyruvate), PK (50 mM HEPES pH 7.4, 0.1 M KCl, 10 mM MgCl2,
0.2mMNADH, 5mMphosphophenolpyruvate, 5mMADP pH 6.8,10 μM
fructose-1, 6-bisphosphate, and 10 U/ml LDH), and G3PDH (40 mM
bicine, 0.8 M sodium acetate, 0.8 mM EDTA, 25 mM sodium arsenate,
0.5 mM NAD+, and 1 mM glyceraldehyde 3-phosphate). Hexokinase
(HK) and phosphoglucoisomerase (PGI) assays were linked to a glucose
6-phosphate dehydrogenase (G6PDH) catalyzed reaction. The buffers
for these assays were as follows: HK (50 mM HEPES pH 7.4, 5 mM
MgCl2, 2 mM NAD+, 0.5 mM NADP+, 1 mM ATP, 5 mM dithiothreitol,
5 mM glucose, 10 U/ml glucose 6-phopshate dehydrogenase), and
phosphoglucoisomerase (50 mM Tris pH 8.1, 0.5 mM NADP+, 5 mM
dithiothreitol, 0.5 mM fructose 6-phosphate, and 10 U/ml glucose 6-
phopshate dehydrogenase). Complex II was assayed in 20 mM
potassium phosphate buffer (pH 7.4) with 20 mM succinate, 65 μM
ubiquinone-2, and 0.1 mM dichlorophenol indophenol. Complex III was
assayed in 20 mM potassium phosphate buffer (pH 7.4) with 65 μM
ubiquinol-2 and 50 μM oxidized cytochrome c. Ubiquinol was prepared
by dissolving ubiquinone in 2 ml ethanol, diluting with 15 ml 0.1 M
potassium phosphate (pH 7.4) and 250 mM sucrose, reducing with
sodium dithionite, and extracting three times with 2 ml cyclohexane,
and dried under a stream of nitrogen. All enzyme analyses were
normalized to the concentration of protein in the samples.
2.5. Nucleic acid extraction and real-time PCR
Cells used for RNA analysis were homogenized in buffer RLT using
a 21-gauge needle and RNA was extracted using the RNeasy
extraction kit (Qiagen, Mississauga, ON). Complimentary DNA was
synthesized using AMV RT (Promega, Madison, WI), oligo (dT)
primers, and random hexamers as per manufacturer's instructions.
Real-time PCR was performed using 50 ng of cDNA, 0.58 μM of the
appropriate primers (Table 1), 12.5 μl of SYBR green (Qiagen,
Mississauga, ON) and 3.5 μl of water. An Applied Biosystems 7500Table 1
Real-time PCR human-speciﬁc primers.
Gene (accession no.) Forward primer (5′-3′) Reverse primer (5′-3′)
TBP (NM003194) cagtgacccagcagcatcact aggccaagccctgagcgtaa
HIF-1α (NM001530) [24] ctagccgaggaagaactatgaacat ctgaggttggttactgttggtatca
VEGF65 (NM001025366) ccctgatgagatcgagtacatctt agcaaggcccacagggattt
VEGF212 (NM001025367) ccctgatgagatcgagtacatctt gcctcggcttgtcacattt
SREBP-1a (NM004176) aggcggctttggagcag agcatgtcttgtcacattt
SREBP-1c (NM001005291) gccatggattgcacttt caagagaggagctcaatg
SREBP-2 (NM004599) cccctgacttccctgctgca gcgcgagtgtggccggatc
SCAP (NM012235) tgctcaccgtggggatgt cactgctgatgacacaggaggt
FAS (NM004104) caagcaggcacacacgatgg ggtctcggctcagggcctcc
ACC1 (NM001093) ctgacgaggactctgttgc ggtggagtcccgacatgct
HKII (NM000189) acggagctcaaccatgaccaa ccatctggagtggacctca
LDHa (NM005566) tggcctgtgccatcagtatct gccgtgataatgaccagcttg
PKm (NM002654,
NM182470, NM182471)
caccgcaagctgtttgaa tgccagactccgtcagaact
ALDOa (NM000034,
NM184041, NM184043)
ctggctgctgtctacaaggct cctcctcactctggcctcc
PGC-1α (NM013261) caggtatgacagctacgaggaa tgcctctgcctctcccttt
NRF-2α (NM002040) ttccagcatcagtgcaatct ctgaaatcctcggcgctct
COXIV (XM008055) [46] cctcctggagcagcctctc tcagcaaagctctccttgaactt
COXI (NM536845) [26] ttcgccgaccgttgactattctct aagattattacaaatgcatgggc
CS (NM004077, NM198324) gcctgtacctcaccatccca tttgccaacttccttctgca
p53 (NM000546.4) ctgctcagatagcgatggtctg ttgtagtggatggtggtacagtca
SCO2 (NM005138.2) cttcactcactgccctgaca cggtcagacccaacagctt
mtDNA (COX I) acgccataaaactcttcaccaaag gggttcatagtagaagagcgatggreal-time PCR system (ABI, Foster City, CA) was used under the
following conditions: a 95 °C denaturation phase for 15 min followed
by 40 cycles consisting of 15 s at 95 °C, 30 s at the optimal annealing
temperature and 36 s at 72 °C. All primers (Table 1) were designed to
be human-speciﬁc and were tested on mouse tissue to ensure no
ampliﬁcation would occur due to residual mouse tissue from
xenografts. Primers were designed to ﬂank intron–exon boundaries
whenever possible to distinguish ampliﬁcation of genomic DNA. All
mRNA levels are expressed relative to the housekeeping gene TATA-
binding protein (TBP).
Cells used for DNA analysis were extracted in enzyme extraction
buffer then digested overnight with proteinase K (0.2mg/ml) at 55 °C.
Solutions were extracted with an equal volume of phenol:chloroform:
isoamyl alcohol (25:24:1), with the DNA precipitated from the upper
aqueous phase with 0.5 vol 7.5 M ammonium acetate and 2 vol 100%
ethanol. After overnight at −20 °C, DNA was collected by centrifuga-
tion and resuspended in water. Total DNA (1 ng/reaction) was
subjected to real-time PCR using primers for mtDNA.
2.6. Intracellular ATP levels
After growing cells to 80% conﬂuency, the medium was replaced
and cells were exposed to control, acidic (pH 6.2), hypoxic, or acidic
and hypoxic conditions for 72 h. Cellular ATP levels were determined
in acid extracts of cells. After treatment, the supernatant was
collected and pooled with trypsinized cells. After removing 10% of
the cells for protein determination, the remaining cells were
sedimented (5 min at 200 g) and the pellets were acidiﬁed (0.5 ml
of 3% perchloric acid). After centrifugation, 400 μl of the supernatant
was neutralized with 50 μl saturated Tris base, 50 μl 2 M KCl, and 150 μl
2 M KOH with trace amounts of phenol red as a pH indicator. ATP
standards were prepared in a solution that had been acidiﬁed and
neutralized in the same manner as the cellular extracts. Standards and
extractswere analyzed for ATPusing a luciferin–luciferase assaymixture
(Sigma) on an LMax luminometer (Molecular Devices, Sunnyvale, CA).
Cellular ATP levelswere then normalized to the protein concentration in
each sample.
2.7. Cardiolipin content (NAO staining)
Mitochondrial content was determined by staining the cells with
nonyl acridine orange (NAO) (AnaSpec, San Jose, CA), a dye that
quantiﬁes mitochondrial mass by binding to cardiolipin in mitochon-
dria, regardless of their energetic state. In brief, cells were grown in
clear medium, and were treated with 100 nM NAO for 30 min.
Following treatment, cells were washed, trypsinized with clear
trypsin, centrifuged for 5 min at 500 g, and resuspended in PBS for
analysis by ﬂuorescence activated cell sorting (FACS).
2.8. Xenografts in SCID mice
For sub-renal capsule grafting of LNCaP cells, 1–5×105 cells were
embedded in 50 μl rat tail collagen as described previously [24]. After
an overnight incubation at 37 °C, the collagen gels were grafted under
the kidney capsule of testosterone-supplemented, castrated adult
male severe combined immunodeﬁcient (SCID) mice (Harlan,
Indianapolis, IN). LNCaP-luc tumors were generated by intra-femoral
injections of twenty ﬁve thousand cells into adult male SCID mice.
Tumors formed from outgrowths from the injection sites in the femur,
into the surrounding legmuscle. After 28 days, all micewere sacriﬁced
and tumors harvested and snap-frozen in liquid nitrogen.
2.9. Triglyceride extraction and quantiﬁcation
Lipids were extracted from prostate cancer cells using a modiﬁca-
tion of the Folch method [25]. Brieﬂy, cell pellets were dissolved in
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3000 g. The resulting mixture was ﬁltered and then 0.25 vol of 0.25%
KCl was added to remove the water-soluble compounds. Following
separation of the two phases and removal of the aqueous phase by
vacuum, the nonaqueous phase was evaporated under nitrogen gas at
60 °C and resuspended in isopropanol. Standards were also dissolved
in isopropanol. The triglyceride in the resulting extracts were then
quantiﬁed using the TRIGS kit (Randox, Mississauga, ON), which uses
an enzymatic method to quantify triglyceride after enzymatic
hydrolysis with lipases.
2.10. Statistical analyses
Each treatment was tested for both normality using the Shapiro–
Wilk test and for equal variance using the O'Brien test. If the datawere
normally distributed and had equal variance, then a one-way analysis
of variance (ANOVA) was performed to assess if differences existed
between groups followed by a Tukey–Kramer HSD test to identify
which groups were different. If the data were not normally
distributed, then the non-parametric Wilcoxon test was used. For
dichloroacetate studies, a dependent Student's t-test was used to
determine if the effects of the drug were signiﬁcant following
treatment. All tests were performed using JMP statistical software.
For our experiments, data are deemed signiﬁcantly different if the p
value for the comparison is less than 0.05.Fig. 1.Metabolism of LNCaP, DU145, and PC3 cells. Basal rates of (A) O2 consumption and (B)
panels C (lactate production) and D (ATP levels). Cells were grown for 12 h in medium
measurements were performed on cells grown 12 h with sodium azide. As well, ATP measure
show the effects of a 48 h treatment with 0.5 mMdichloroacetate (DCA) onmetabolism, both
untreated cells in each cell line. Panel G shows the effects of acute treatmentwith 0.1 μMDNP
Panel H shows estimates of mitochondrial content based upon the median ﬂuorescence of ce
repeated on six different days with median ﬂuorescence levels expressed relative to the m
statistically indistinguishable groups within a panel (A, B) or cell line (C–H), assessed using3. Results
3.1. The metabolic phenotype differs between cell lines
To determine metabolic differences between prostate cancer cell
lines, we evaluated rates of oxygen consumption and lactate
production, and levels of ATP. We also explored how hypoxia and
low pH inﬂuenced their respective metabolic patterns.
The metabolic phenotype of LNCaP cells differed from that of
DU145 and PC3 cells; LNCaP cells had a signiﬁcantly greater oxygen
consumption rate (Fig. 1A), as well as a signiﬁcantly lower rate of
lactate production (Fig. 1B). The relative importance of OXPHOS and
glycolysis can be estimated from these data, assuming 1 nmol O2
consumed equates to 5 nmol ATP produced, and 1 nmol lactate
produced equates to 1 nmol ATP produced. With these assumptions,
OXPHOS contributed 88% of ATP demands in LNCaP cells, but only 56%
in PC3 and 47% in DU145 cells.
The three cell lines also differed in their response to oxygen supply
and OXPHOS inhibition (Fig. 1C). LNCaP cells were most affected,
increasing their lactate production rate nearly 3-fold under hypoxia
and about 4-fold with either anoxia or azide treatment. The PC3 cells
also showed an increase in lactate production with these treatments,
though the maximal stimulation was only about 2-fold. DU145 cells
signiﬁcantly increased their production of lactate following treatment
with anoxia and azide, but not hypoxia. The greater sensitivity of LNCaPlactate production (n=5). The effects of hypoxic medium on metabolism are shown in
in normoxic, hypoxic (2% O2) or anoxic medium (0% O2) (n=5). In addition, lactate
ments were performed on cells treated with acidic and hypoxic medium. Panels E and F
cellular respiration (E) and lactate production (F) (n=6). Data are expressed relative to
on cellular respiration, with data expressed relative to the untreated cell in each cell line.
lls sorted by FACS after loading with NAO (nonyl acridine orange). The experiment was
aximum value for each run (n=6). Bars are means (+SEM). Common letters denote
an ANOVA and Tukey post hoc tests.
Fig. 2.Metabolic gene mRNA levels and select enzymatic activities in LNCaP, DU145, and PC3 cells. Panels A–C show mRNA levels for select metabolic genes were measured by real-
time PCR, using TATA-binding protein as an internal housekeeping gene. All transcript levels are scaled in relation to LNCaPmRNA, and expressed asmean+SEM (n=6). For panel D,
all enzyme levels are scaled relative to LNCaPmeans (n=6). Actual Vmax measurements for each enzyme were (in nmol/min/mg protein): PK 4.3±0.12, LDH 2.9±0.2, PGI 2.7±0.1,
G3PDH 1.2±0.03, HK 0.1±0.007, COX 0.013±0.001, CS 0.386±0.015, Complex II 0.019±0.002, Complex III 0.0083±0.0004. Common letters denote statistically indistinguishable
cell lines for a given mRNA or enzyme. Statistical differences were identiﬁed using non-parametric Wilcoxon tests (mRNA) or ANOVA and Tukey–Kramer tests (enzymes).
Table 2
Relative mtDNA levels in ﬁve prostate cell lines.
Line Mean SEM Signiﬁcant
differences1
LNCap 1.00 0.16 a, b
LNCap-luc 1.43 0.07 a
HP-LNCap 0.78 0.15 b
DU145 0.69 0.07 b
PC3 0.70 0.13 b
1 Levels connected by the same letter are not signiﬁcantly different, as assessed with
a Tukey–Kramer HSD test.
1437L.H. Higgins et al. / Biochimica et Biophysica Acta 1787 (2009) 1433–1443cells to OXPHOS limitations was also reﬂected in ATP levels (Fig. 1D).
LNCaP cells had 4-fold higher ATP levels than DU145 and PC3 cells
under normoxic conditions, and respondedmuchmore dramatically to
low oxygen treatments. When exposed to hypoxia, ATP levels declined
by 50% in LNCaP cells, but were unaffected in PC3 and DU145 cells.
We also assessed the ability of these cells to respond to DCA, a
stimulator of pyruvate dehydrogenase (PDH) that acts via inhibition of
PDH kinase [15]. DCA increased the oxygen consumption rate in LNCaP
cells, but had no effect on DU145 or PC3 respiration rates (Fig. 1E).
Moreover, DCA did not signiﬁcantly inﬂuence the lactate production
rates in any of the cell lines evaluated (Fig. 1F). Collectively, these
studies suggest that LNCaP cells have normal mitochondrial metabo-
lism but both the PC3 and DU145 cells suffer some degree of
mitochondrial impairment that accompanies glycolytic stimulation.
To conﬁrm our hypothesis that the glycolytic cell lines DU145 and
PC3 sufferedmitochondrial impairment, we tested the ability of DNP, a
mitochondrial uncoupler, to stimulate mitochondrial respiration. DNP
more thandoubled respiration in theLNCaP cells, buthad lessof aneffect
on PC3 cells (increase of 42%) and no effect on DU145 cells (Fig. 1G).
WeusedNAO,aﬂuorescent ligandof themitochondrial phospholipid
cardiolipin to assess if thedifferences inmitochondrial enzymeactivities
were simply differences in mitochondrial content (Fig. 1H). None of the
cell lines showed differences in cardiolipin content, suggesting LNCaP
cells had the same number of mitochondria. Thus, where cells possess
lower mitochondrial enzymatic activities (per mg cellular protein), this
is attributed to lower mitochondrial enzyme speciﬁc activities per
mitochondria rather than simply fewer mitochondria.3.2. DU145 and PC3 cells have selectively reduced mitochondrial enzyme
activity but not mitochondrial gene expression
Next we focused on how the three lines differed in the expression
of genes for metabolic enzymes and their regulators (Fig. 2A–C), as
well as the resulting catalytic activities (Fig. 2D). Although there were
no consistent enzymatic differences in the glycolytic pathways in the
three cell lines, DU145 and PC3 cells possessed less than half the
activities of the mitochondrial enzymes CS, COX and Complex III but
no reduction in Complex II (Fig. 2D) or mtDNA copy number (Table 2).
There were pronounced differences in the expression of genes
linked to the hypoxic response (Fig. 2A). PC3 cells showed elevated
mRNA levels of a broad suite of hypoxia-related genes including HIF-1α
(30-fold), two VEGF isoforms (30-fold), and each glycolytic gene we
studied (5- to 10-fold). DU145 had intermediate transcript abundance,
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the elevations in the expression of glycolytic enzymes.
There were also differences in the transcript levels of genes linked to
mitochondrial metabolism (Fig. 2B). Despite lower mitochondrial ﬂux
(Fig. 1) and lower mitochondrial enzyme activities (Fig. 2D), both
DU145 and PC3 cells showed an apparent stimulation of multiple genes
for mitochondrial enzymes (Fig. 2B). DU145 cells possessed more
abundant transcripts for COXIV, COXI, CS, and the COX assembly factor
SCO2, whereas PC3 cells had high NRF-2 and SCO2 transcript levels.
Although there were remarkable line-speciﬁc differences in both
glycolytic and mitochondrial gene expressions, there were only
modest differences in the expression of genes linked to fatty acid
metabolism (Fig. 2C). The two glycolytic cell lines had signiﬁcantly
greater mRNA levels for SREBP-1a, SREBP-2, and SCAP but lower
mRNA for SREBP-1c, the isoform linked to lipogenesis. There were no
signiﬁcant differences between cell lines in FAS mRNA, but the mRNA
for ACC1 was signiﬁcantly greater in the DU145 and PC3 cells.Fig. 3. Comparison of HP-LNCaP and LNCaP-luc cells. Panels A–C show mRNA levels for sele
internal housekeeping gene. All transcript levels are scaled in relation to LNCaP mRNA, and
LNCaP means (n=6). Panels D–F summarize the metabolic differences between LNCaP pare
as described previously for mRNA, (A–C, as in Fig. 2), respiration (D, as in Fig.1), lactate produ
(+SEM) with different letters denoting signiﬁcantly different values within each cell line.3.3. LNCaP cells transition to a glycolytic phenotype with increasing
passage and clonal selection
We studied two lines of LNCaP cells that had been subjected to
repeated passage number, with or without clonal selection (LNCaP-luc
and HP-LNCaP, respectively). We also used these cells to assess the
plasticity of the metabolic phenotype in vivo.
Both lines showed a signiﬁcant “hypoxic response” in terms of
elevations in mRNA for HIF-1α, VEGF, and selected glycolytic genes
(Fig. 3A). In comparison to the LNCap cells grown in vitro, LNCaP-luc
cells grown in vitro demonstrated elevated HIF-1α and PKm mRNA
levels. The same trend was seen in HP-LNCaP cells, though less
markedly (Fig. 3A). There was no uniform pattern seen in mitochon-
drial gene expressionwith passage. HP-LNCaP cells had a signiﬁcantly
higher expression of PGC-1α, NRF-2 and COX1; LNCaP-luc cells had
elevated expression of NRF-2, COXIV and COXI (Fig. 3B). There were
also differences seen in the SREBP axis (Fig. 3C); LNCaP-luc cellsct metabolic genes were measured by real-time PCR, using TATA-binding protein as an
expressed as mean+SEM (n=6). For panel D, all enzyme levels are scaled relative to
nt and derived lines in respiration. Additional details for measurements and analysis are
ction (E, as in Fig.1), andmitochondrial enzyme activities (F, as in Fig. 2). Bars aremeans
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elevations in SCAP. HP-LNCaP cells had increased expression of SREBP-
1a, SCAP, and ACC1 compared to the parent line (Fig. 3C). Though
passage altered the expression of several mitochondrial genes in HP-
LNCaP cells, the LNCaP-luc cells were more similar to the low passage
parental line.
In both lines, prolonged passage under normoxia reduced the rates
of oxygen consumption (Fig. 3D) and increased the rate of lactate
production (Fig. 3E). The high passage lines achieved a metabolic
phenotype similar in most respects to the PC3 and DU145 cells.
Complex II activities in derived lines were elevated about 40% over the
parental line. The LNCaP-derived lines showed different patterns in
terms of other mitochondrial enzyme properties. LNCaP-luc cells
showed approximately 50% reductions in CS, COX and Complex III (Fig.
3F), which is similar to what was seenwith PC3 and DU145 (Fig. 2). In
contrast, HP-LNCaP cells possessed CS, COX and Complex III activities
that were near that of the parental line. The levels of mtDNA were
elevated by 40% in LNCaP-luc cells but unaffected in HP-LNCaP cells.
3.4. Metabolic gene expression of LNCaP cells in vivo
To investigate whether mRNA levels differ between cells grown in
vitro and in vivo, we analyzed expression proﬁles of HP-LNCaP and
LNCaP-luc cells grown as xenografts in SCID mice.
HP-LNCaP xenografts were grown in vitro and as kidney xenografts
and examined for mRNA levels (Fig. 4A, B) The xenografts had
signiﬁcantly greater mRNA levels of HIF-1α and VEGF65 than cellsFig. 4. Transcript levels on LNCaP-luc cells and xenografts. Bars represent mean (+SEM) m
panels A–C, an asterisk denotes groups that are signiﬁcantly different from in vitro cells. For
Data were analyzed using non-parametric Wilcoxon tests.grown in vivo; however, the only notable change in the glycolytic
genes was a signiﬁcant decrease in ALDOa transcript abundance in
vivo (Fig. 4A). In comparison to cells grown in vitro, HP-LNCaP
xenografts showed an increase in the levels of PGC-1α (7-fold), COXIV
(3-fold) and COXI (5-fold) mRNA levels (Fig. 4B). In terms of
lipogenesis, xenografts displayed a signiﬁcantly lower abundance of
SREBP-1c and ACC1 transcripts, but a 5-fold increase in SCAP mRNA
levels (Fig. 4C).
LNCaP-luc cells were grown as xenografts in kidney and leg muscle
(Fig. 4D–F). There were few notable differences in these cells when
grown in the different contexts. There was some evidence of a hypoxic
response in both LNCaP-luc xenografts in vivo, with elevations in
mRNA of one VEGF isoform (muscle only) and selected glycolytic
enzymes (HKII, PKm) (Fig. 4D). Both kidney and muscle xenografts
showed an increase in COXI mRNA (Fig. 4E). There were few
differences in themRNA of the SREBP axis of gene expression (Fig. 4F).3.5. SREBP axis gene expression is not hypoxia sensitive
Cells were exposed to normoxia, hypoxia, or anoxia for 12 h to
determine the sensitivity of the SREBP axis to low oxygen (Fig. 5). In
each cell line, the levels of VEGF mRNA (a HIF-1 target) signiﬁcantly
increased following treatment with anoxia. Anoxic treatment of
LNCaP and PC3 cells (though not DU145 cells) also increased the
abundance of HKII transcripts, another HIF-1 target. Less of a response
was seen with hypoxia for these two genes known to be HIF targets.RNA levels displayed relative to transcript levels in cell line grown in vitro (n=6). For
panels D–F, different letters denote signiﬁcantly different values within each transcript.
Fig. 5.mRNA levels in prostate cells following exposure to normoxia, hypoxia or anoxia for 12 h. The mRNA levels are depicted for the hypoxia response genes HKII (A) and VEGF (B),
the SREBP downstream targets FAS (C) and ACC1 (D), the transcription factors SREBP-1a (E) and SREBP-1c (F), and the cleavage activating protein SCAP (G). Bars represent mean
mRNA levels (+SEM) displayed relative to control transcript levels. ⁎Indicates signiﬁcant difference from normoxic controls within each cell line according to non-parametric
Wilcoxon tests (n=5).
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on themRNA levels of FAS, ACC1, or SCAP in any cell line (Fig. 5C, D, G).
PC3 cells, but not the other lines, showed a signiﬁcant increase in the
levels of SREBP-1a and SREBP-1c mRNA (Fig. 5E, F).
We also conducted parallel studies using sodium azide under
normoxia to see if potential effects of oxygen reductions could be due
to secondary effects on metabolism. However azide treatment of
normoxic cells had no signiﬁcant effect on any transcript we measured
(data not shown).
3.6. Triglyceride levels are not inﬂuenced by low oxygen in these prostate
cancer models
Cells were exposed to normoxia, hypoxia, and anoxia for a 48-hour
period to determine the inﬂuence of low oxygen on their steady-stateFig. 6. Triglyceride content (μg TG/mg protein) of LNCaP, DU145, and PC3 cells following
48 h exposure to normoxia, hypoxia, and anoxia. Bars represent means (+SEM) in
triglyceride levels in prostate cancer cells under normoxic and low oxygen conditions.
There were no signiﬁcant effects of hypoxia or anoxia on triglyceride content, as
assessed by non-parametric Wilcoxon tests (n=6).triglyceride levels (Fig. 6). No signiﬁcant differences were noted
between the control samples and the low oxygen treatments for any of
the cell lines (Fig. 6).
4. Discussion
We found that the three classical prostate cancer cell lines (LNCaP,
DU145, PC3) show dramatic differences in their metabolic pheno-
type. LNCaP cells are highly oxidative in contrast to both DU145 and
PC3 lines. That is, LNCaP cells have higher rates of oxygen consump-
tion and lower rates of lactate production in comparison to the other
lines.
4.1. Metabolic enzyme activities and gene expression
We found the cancer lines to show a general maintenance in
glycolytic enzyme activities and stoichiometries, but there were
intriguing differences in other aspects of the glycolytic phenotype.
Despite the similarities in enzyme speciﬁc activities, the three cell
lines differed in glycolytic rate. As well, there was little relationship
between transcript abundance and enzyme activities; PC3 cells
showed higher mRNA levels for all glycolytic enzymes studied. This
is likely attributed to differential post-transcriptional regulation of
speciﬁc mRNAs encoded by glycolytic genes. Though there are many
ways to regulate glycolytic gene expression, an adaptive increase in
glycolytic enzymes with hypoxia is typically mediated by HIF [13].
When grown under the same normoxic conditions as LNCaP cells,
both PC3 and DU145 cells showed circa 10-fold higher HIF-1α mRNA
levels. Though the most important mechanism for HIF-dependent
stimulation of gene expression is via post-translational stabilization of
HIF-1α [26], HIF-1α can also be regulated transcriptionally [27].
Elevated basal HIF-1 activity is noted in many cancers, including those
that retain an ability to respond to hypoxia [28]. It is noteworthy that
PC3 and DU145 showed high levels of mRNA for HIF-1α as well as HIF
target genes such as VEGF isoforms (PC3 and DU145) and multiple
glycolytic genes (PC3 only) (Fig. 2A). The mechanism that leads these
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conditions was not explored in this study.
The glycolytic reliance of PC3 and DU145 cells is most likely due
to OXPHOS insufﬁciency. The story that emerges from our studies is
that in these cells, the reduced reliance on OXPHOS is due to a
mitochondrial dysfunction. PC3 and DU145 cells showed lower
respiration rates that could not be markedly stimulated by an
uncoupler (Fig. 1G). Though the three cell lines possessed a similar
amount of inner mitochondrial membrane (an estimate of mito-
chondrial content) (Fig. 1H), PC3 and DU145 cells had 35–50% of the
activities of three mitochondrial enzymes (Complex III, COX and CS)
compared to LNCaP cells (Fig. 2D), despite similar mtDNA levels
(Table 2). Though the cells possessed lower mitochondrial enzyme
activities (except Complex II), they appeared to attempt to stimulate
mitochondrial biogenesis. DU145 cells show 5-fold higher mRNA
levels for mitochondrial enzymes (CS and COX subunits) and both
glycolytic lines showed elevated mRNA levels for important regu-
lators of mitochondrial biogenesis (PGC-1α and NRF-2) (Fig. 2B).
These observations suggest that the most parsimonious explanation
for depressed mitochondrial enzyme levels is a disruption of
mitochondrial biogenesis, rather than a regulated decrease in the
content of otherwise normal mitochondria. In terms of metabolic
ﬂuxes, the DU145 and PC3 cells compensate for the reductions in
OXPHOS by stimulating glycolysis, through the normal allosteric and
covalent regulators of glycolysis without a need to elevate glycolytic
enzyme levels.
Such differences in the relative importance of OXPHOS would be
expected to inﬂuence the efﬁcacy of drugs with metabolic targets. For
example, DCA has been proven successful at reversing the glycolytic
phenotype of non-small-cell lung cancer by simultaneously increas-
ing the oxidation of glucose in the mitochondria, and decreasing the
rates of lactate production and fatty acid oxidation [15]. Though
LNCaP cells did increase their rate of respiration when treated with
DCA, the other two cell lines were unresponsive to the treatment.
Thus, our studies suggest that the small molecule DCA exerts its
greatest effects on metabolism in cells with an oxidative metabolic
poise.
The exact origins of the mitochondrial defects in the PC3 and
DU145 lines remain unclear. Although the PC3 and DU145 cells
possessed lower mitochondrial enzyme levels, they showed an
apparent stimulation of genes associated withmitochondrial enzymes
and their regulators. This would appear to represent a futile effort to
stimulate mitochondrial biogenesis, perhaps in response to energetic
shortfalls. The resulting state is fairly characterized as a mitochondrial
lesion, where defects in one or more critical enzymes lead to an
inability to sustain mitochondrial biogenesis. In other situations,
mitochondrial lesions are attributed to defects in COX [29], including
defects in processing of the heme and copper groups that are essential
for the holoenzyme [30]. Matoba et al. [11] proposed that a loss of p53
activity might reduce COX levels by inhibiting the expression of the
SCO2 gene, which encodes a protein that participates in copper
delivery to the mitochondria. Though we have demonstrated that
DU145 and PC3 cells have reduced COX enzyme activities, and these
lines have previously been characterized to lack functional p53 [31],
their SCO2 expression is no different from that of the LNCaP cells.
Thus, the reductions in mitochondrial enzymes in PC3 and DU145
cells cannot be explained by reduced transcription of (i) the
transcriptional regulators of mitochondrial biogenesis (PGC-1α,
NRF2), (ii) the genes encoding the oxidative enzymes or (iii) the
SCO2 assembly factor.
4.2. The effects of passage and selection
Interestingly, we found that many of the differences seen between
LNCaP and the glycolytic cells were recapitulated in the LNCaP line
when it was subjected to high passage, with or without clonalselection. Both HP-LNCaP and LNCaP-luc cells were more glycolytic
than the parental line (i.e., lower respiration rate and higher rate of
lactate production). There were reductions in mitochondrial enzymes
(without changes in mitochondrial inner membrane/cardiolipin
levels) coupledwith increases in themRNA formitochondrial proteins
and regulators of mitochondrial gene expression.
Like the DU145 and PC3 cells, increases in HIF1αmRNA in LNCaP-
derived cells were accompanied by modest increases in expression of
HIF targets (VEGF) and select glycolytic enzymes. Bordeau-Heller and
Oberley [15] demonstrated that following prolonged culture in
hypoxic conditions DU145 cells signiﬁcantly reduced their rate of
oxygen consumption and increased HIF-1α protein levels. However, in
our study, the metabolic transformation that occurred in the LNCaP
cells occurred when grown and passaged under normoxia. It is not
clear whywe saw elevated HIF1αmRNA in the glycolytic lines because
HIF activity is most commonly regulated though post-translational
mechanisms. The increases in mRNA for diverse HIF target genes
suggest this pathwaywas stimulated and that transcription regulation
of HIF1α might contribute to the effect. However, the underlying
mechanism bywhich HIF1α expression is stimulated remains unclear.
It is not clear as to the extent to which the metabolic phenotype of
the parent cell lines reﬂects the properties of the tumor fromwhich it
came, or prostate cancers in general. While aerobic glycolysis is an
important characteristic of prostate cancer cells, the evolution of this
phenotype in vivo is not yet clear. Somatic evolution during
carcinogenesis usually involves the combination of genetic events
such as proto-oncogene gain-of-function, loss of tumor suppressor
function, and environmental selection [32,33]. Since these cells can
manage differences in glycolytic metabolismwith the similar activities
of enzymes, the problem would seem to lie in the mitochondrial
capacity. This would explain why the glycolytic phenotype remains
when oxygen is abundant (e.g., [10]).
4.3. On the nature of mitochondrial differences
Collectively, these studies on mitochondrial properties illustrate
the magnitude of variation in metabolic poise seen in the cell lines
commonly used to explore prostate cancer.We see evidence of a defect
in mitochondrial function in two of the independent lines (DU145,
PC3), one of the LNCaP-derived lines (LNCaP-luc) and a trend toward a
similar phenotype in the other derived line (HP-LNCaP). The origins of
these defects and the underlying mechanism remain uncertain at this
time. The LNCaP parental appears to be a cell line with an oxidative
poise and anticipated responses to mitochondrial effectors. Thus, we
use this line as a basis to compare alternate lines (DU145, PC3) and
derived lines (HP-LNCaP, LNCaP-luc). Each of these four lines is
glycolytic in nature, with depressed oxygen consumption, elevated
glycolytic rates, and reduced responsiveness to mitochondrial stimu-
lators or hypoxia (Figs. 1 and 2). The HP-LNCaP cells are more like the
parental cells in metabolic and enzyme properties but there is
considerable similarity in the patterns seen in the three other lines
of independent origins. It appears that the glycolytic cell lines possess
mitochondria that are in some way dysfunctional. It is intriguing that
the three cell lines appear to have converged on a common
dysfunction: deﬁciencies in CS, COX, and Complex III. They are not
deﬁcient in cardiolipin content/inner membrane (Fig. 1H), mtDNA
copy number (Table 2), or Complex II catalytic activity (Figs. 2D, and
3D). This is not explained by simple reductions in inner membrane
surface area because (i) cardiolipin is unaffected, (ii) the CS (a matrix
enzyme) is also depressed, and (iii) Complex II (a membrane enzyme)
is unaffected. It is not a simple reduction in global mtDNA expression
because (i) mtDNA copy number is unaffected and (ii) COX I
transcripts are elevated (unaffected in LNCaP-luc). There are a number
of indices that suggest cells are attempting to rectify the shortfall in
mitochondrial capacity, including elevated mRNA for COX subunits (I,
IV) and mRNA regulators of mitochondrial gene expression (PGC1α,
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and Complex III is that these lines have defects in mtDNA translation
and/or mutations in subunits. However, the depression of CS activity
would not be directly affected by such mutations.
4.4. In vivo and in vitro differences in gene expression
Cell culturemodels are commonly used in cancer biology, however,
relatively little is known about how metabolic gene expression in
cultured cells relates to gene expression in vivo. In vitro, there is a tight
relationship between gene expression, growth factor signaling,
proliferation and treatment efﬁcacy [34–36]. In vivo oncogenesis is
muchmore complex for it requires the development of a new vascular
network to allow individual cells to be perfused with oxygen and
nutrients from the circulation. The microcirculation and degree of
vascularization of a particular tumor inﬂuences the degree of hypoxia
and acidosis in its microenvironment [37]. Therefore gene expression
in vivo may be governed by the interplay between the endogenous
metabolic phenotype of a cell and the environment inwhich it is found.
To explore this question, we studied two derived lines of LNCaP
cells to assess how expression patterns were affected by growth in a
more complex tumor environment (Fig. 4). HP-LNCaP tumor were
grown as kidney xenografts and LNCaP-luc cells were grown as
xenografts in both kidney (highly perfused) and leg muscle (less
vascularized). This allowed us to compare metabolic gene expression
patterns arising (i) from in vitro versus in vivo growth, (ii) in different
LNCaP-derived lines in vivo, and (iii) in a single cell line grown as
different xenographs. When comparing kidney xenografts of HP-
LNCaP and LNCaP-Luc cells, only the former had a hypoxic response
(i.e., increase in VEGF65), as well as a much greater stimulation of
mitochondrial gene expression (COXI, COXIV, PGC-1α). In fact, LNCaP-
Luc cells showed few differences in mRNA for mitochondrial and
glycolytic genes comparing growth in vitro and in vivo. The
insensitivity of this line to growth conditions in kidney xenografts is
in agreement with the ﬁndings of Kallinowski et al. [37], who
demonstrated that the balance between glycolysis and OXPHOS in
xenografts is determined independently of oxygen and glucose
delivery. The LNCaP-Luc lines did, however, differ when comparing
kidney versus muscle xenografts. Consistent with the expectation that
muscle xenografts would be less vascularized than kidney xenografts,
muscle xenografts demonstrated elements of a hypoxic response:
elevated mRNA for VEGF65 and several glycolytic enzymes.
Growth context also had complex effects on components of the
SREBP axis. Growing HP-LNCaP cells as kidney xenografts led to a
reduction in mRNA levels for SREBP-1c and ACC1 but an increase in
SCAP. In contrast, there were no signiﬁcant differences in any of the
SREBP axis when comparing LNCaP-Luc cells grown in vitro versus in
vivo as kidney xenografts. In comparison to kidney xenografts, muscle
LNCaP-luc xenografts had a slightly higher mRNA for both SREBP-2
and FAS, but lower ACC1 mRNA.
Apart from many hallmarks of a hypoxic response, there were few
universal patterns that arose when these cells were in different
contexts, suggesting that the metabolic phenotype of tumor cells
grown as xenografts is dependent primarily on their genotype though
also inﬂuenced by the local environment and/or interactions with the
surrounding tissue.
4.5. Lipid synthesis, the SREBP axis and hypoxia
Prostate and many other cancers accumulate high intracellular
levels of lipid through de novo fatty acid synthesis [38–41]. Several
reasons for this increased capacity for fatty acid synthesis in cancers
have been proposed. It is generally held that elevated fatty acid
synthesis is needed to support membrane biosynthesis in the rapidly
dividing cells [42]. In contrast, Hochachka et al. suggested that fatty
acid synthesis may play an important role in regulating redox balancein cancer cells, much like the situation seen in hypoxia-tolerant
invertebrates [38]. Regardless of the underlying role, it is clear that
fatty acid synthesis is essential for cancer cell survival. Many cancer
cells show an up-regulation of FAS mRNA and protein, as well as a
greater expression of other members of the pathway of de novo fatty
acid synthesis [43–46]. When the expression of ACC or FAS is blocked,
prostate cancer cells show reduced proliferation rates and ultimately
apoptotic death, suggesting that these enzymes may be potential
targets for anti-cancer therapy [47–48]. Our studies on prostate cancer
cells provide some insight into the role of this lipogenic pathway in
cancer metabolism.
Whereas most cells oxidize glycolytic NADH in the LDH reaction
(generating lactate), some organisms oxidize these reducing equiva-
lents by producing fatty acids [38]. Glycolytic NADH is converted to
NADPH via a transhydrogenation reaction and the resultant NADPH is
a substrate for FAS. The relative importance of lactate versus
triglyceride in balancing redox can be estimated from relative rates
of synthesis. A rate of lactate production of 10 nmol/min/mg protein
(Fig. 1) equates to 28.8 μmol NADH/mg protein in a 48 h period. If 14
NADPHmolecules are needed to synthesize a palmitate molecule from
acetyl CoA, then 48.8 nmol NADPH are needed to produce 1 μg
tripalmitate (MW=860). Thus, to match the redox effects of lactate
production over 48 h, the cells would have needed to accumulate an
additional 600 μg triglyceride/mg protein. Baseline levels of triglycer-
ide were approximately 10 μg/mg protein and we saw no change in
triglyceride levels under hypoxia (Fig. 6). Thus, there is little evidence
of a role for triglyceride synthesis in balancing redox in these cells
under normoxia or hypoxia. Furthermore, we found no differences in
baseline triglyceride levels between our prostate cell lines, which have
profound differences in glycolytic ﬂux.
Though it is clear that fatty acid synthesis is important in cancer
cell biology, the relationship between this gene pathway and hypoxia
remains equivocal. The enzymes that mediate lipid synthesis (e.g.,
ACC1, FAS) are regulated in large part by SREBP transcription factors
[49]. We found little effect of in vitro hypoxia on mRNA levels for a
series of genes that are interconnected via the SREBP regulatory
pathway, including FAS and ACC1. This argues against a direct HIF-
mediated sensitivity of the genes of the SREBP axis in these prostate
cancer lines. Recently, Furuta et al. [50] found that FAS mRNA and
protein levels in several breast cancer lines increased in response to
48 h of hypoxia. There could be many reasons for the differences
between our studies. There were differences in the duration of
hypoxic exposure: 12 h in our study versus 48 h in theirs. Since our
12 h hypoxic treatment was sufﬁcient to elicit a metabolic effect (i.e.
stimulation of lactate synthesis) and a prototypical “hypoxia
response” (i.e. increased VEGF mRNA), it seems likely an increase in
FAS mRNA would have been detected if this gene was directly
regulated by oxygen through HIF. The increase in expression of
elements of the SREBP pathway after 48 h hypoxia [50] appeared to
arise indirectly, through a metabolic signaling cascade involving Akt.
We cannot rule out a possibility that a similar indirect effect of hypoxia
would occur in our cells after a longer incubation in hypoxia. There
may also be differences related to the cell types and/or xenograph
approach used by our respective studies. Furuta et al. [50] noted a
pronounced increase in FAS mRNA in breast cancer xenografts grown
in mammary pads of nude mice, whereas we saw no effect on FAS
mRNA in kidney xenografts (HP-LNCap or LNCap-Luc) in SCID mice.
When comparing muscle and kidney xenografts derived from the
same cells (LNCap-Luc), muscle xenografts showed a greater HIF
response (Fig. 4C) as well as increases in mRNA for SREBP-2 (but not
SREBP-1c) and FAS (but not ACC1) (Fig 4D). It is important to note that
the genes of the SREBP axis are also regulated in complex ways by other
factors. For example, regulatory factors such as insulin, epidermal
growth factor and keratinocyte growth factor/ﬁbroblast growth factor 7
can stimulate lipogenic gene transcription (e.g., [51–53]). Thus, our
studies argue against a role for fatty acid synthesis in redox balance
1443L.H. Higgins et al. / Biochimica et Biophysica Acta 1787 (2009) 1433–1443under normoxic or hypoxic conditions in these cells, but there is
conﬂicting evidence about the sensitivity of the SREBP axis to hypoxia.
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